Research@StAndrews
 
The University of St Andrews

Research@StAndrews:FullText >
University of St Andrews Research >
University of St Andrews Research >
University of St Andrews Research >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10023/2250
This item has been viewed 107 times in the last year. View Statistics

Files in This Item:

File Description SizeFormat
Borger_BiochemSocTransact2011_AuthorFinal.pdf337.15 kBAdobe PDFView/Open
Title: Mitochondrial β-amyloid in Alzheimer's disease
Authors: Borger, Eva
Aitken, Laura
Muirhead, Kirsty Elizabeth Adair
Allen, Zoe Eleanor
Ainge, James Alexander
Conway, Stuart
Gunn-Moore, Frank J
Keywords: Alzheimer's disease
Mitochondrial dysfunction
Intracellular Aβ
ABAD
CHANA
Cyclophilin D
QP Physiology
Issue Date: Aug-2011
Citation: Borger , E , Aitken , L , Muirhead , K E A , Allen , Z E , Ainge , J A , Conway , S & Gunn-Moore , F J 2011 , ' Mitochondrial β-amyloid in Alzheimer's disease ' Biochemical Society Transactions , vol 39 , no. 4 , pp. 868-873 .
Abstract: It is well established that the intracellular accumulation of beta-amyloid is associated with Alzheimer’s disease and that this accumulation is toxic to neurons. The precise mechanism by which this toxicity occurs is not well understood, however, identifying the causes of this toxicity is an essential step in developing treatments for Alzheimer’s disease. One intracellular location where the accumulation of beta-amyloid can have a major effect is within mitochondria has identified mitochondrial proteins that act as binding sites for beta-amyloid and when binding occurs a toxic response results. For one of these identified sites, an enzyme known as ‘ABAD’, we have identified the changes in gene expression in the brain cortex following beta-amyloid accumulation within mitochondria. Specifically, we have identified two proteins that are upregulated in the brains of transgenic animal models for Alzheimer’s disease but also human sufferers. The increased expression of these proteins demonstrates the complex and counter-acting pathways that are activated in Alzheimer’s disease. Previous studies have identified the approximate contact sites between ABAD and beta-amyloid, and based on these observations we have shown that using a modified peptide approach, it is possible to reverse the expression of these two proteins in living transgenic animals and also recover both mitochondrial and behavioural deficits. This indicates that the ABAD-beta-amyloid interaction is potentially an interesting target for therapeutic intervention. To explore this further we used a fluorescing substrate mimic to measure the activity of ABAD within living cells, and in addition we have identified chemical fragments that bind to ABAD, by using a thermal shift assay.
Version: Postprint
Description: This research is supported by Alzheimer's Research UK, the Wellcome Trust and the Biotechnology and Biological Sciences Research Council.
Status: Peer reviewed
URI: http://hdl.handle.net/10023/2250
DOI: http://dx.doi.org/10.1042/BST0390868
ISSN: 0300-5127
Type: Journal article
Rights: This is the author's version of this article (c)2011 the authors. The final version of record is available at http://www.biochemsoctrans.org/bst/039/bst0390868.htm
Appears in Collections:University of St Andrews Research
Biology Research
Psychology & Neuroscience Research
Biomedical Sciences Research Complex (BSRC) Research
Institute of Behavioural and Neural Sciences Research



This item is protected by original copyright

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

DSpace Software Copyright © 2002-2012  Duraspace - Feedback
For help contact: Digital-Repository@st-andrews.ac.uk | Copyright for this page belongs to St Andrews University Library | Terms and Conditions (Cookies)